Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Cardiol Therapeutics Inc Class A

Healthcare US CRDL

1.06USD
0.00(0%)

Last update at 2026-06-22T20:00:00Z

Day Range

1.051.07
LowHigh

52 Week Range

0.881.70
LowHigh

Fundamentals

  • Previous Close 1.06
  • Market Cap182.04M
  • Volume280850
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-34.27830M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.08M
  • Diluted EPS TTM-0.28

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -33.81887M -36.67730M -21.22280M -30.93065M -31.63824M
Minority interest - - - - -
Net income -33.81887M -36.67730M -21.22280M -30.93065M -31.63824M
Selling general administrative 20.20M 26.26M 15.56M 22.37M 27.87M
Selling and marketing expenses - - 15.30M - -
Gross profit - - -0.18738M - 0.08M
Reconciled depreciation 0.10M 0.37M 0.24M 0.22M 0.22M
Ebit -34.31630M -40.27665M -21.22280M -50.33903M -45.47313M
Ebitda -34.21431M -40.11454M -21.03541M -50.11913M -45.25271M
Depreciation and amortization 0.10M 0.16M 0.19M 0.22M 0.22M
Non operating income net other - - - - -
Operating income -34.31630M -40.27665M -22.47316M -50.33903M -45.47313M
Other operating expenses 34.32M 40.28M 22.47M 41.34M 38.74M
Interest expense - - - - 0.00000M
Tax provision - - - - -
Interest income 0.73M 1.19M 2.17M 1.24M 0.11M
Net interest income 0.73M 1.19M 2.17M 1.24M 0.11M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 0.00001M -10.24079M -6.91433M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.08M
Total operating expenses 34.32M 40.28M 22.29M 41.34M 38.74M
Cost of revenue - - 0.19M - -
Total other income expense net 0.50M 3.60M 1.25M 9.17M 6.92M
Discontinued operations - - - - -
Net income from continuing ops -33.81887M -36.67730M -28.00629M -30.93065M -31.63824M
Net income applicable to common shares - - - -30.93065M -31.63824M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 23.62M 31.86M 36.70M 62.03M 87.88M
Intangible assets - - 0.21M 0.29M 0.38M
Earning assets - - - - -
Other current assets 1.86M 0.73M 0.94M - -
Total liab 5.74M 7.14M 8.45M 9.83M 11.64M
Total stockholder equity 17.88M 24.73M 28.25M 52.20M 76.24M
Deferred long term liab - - - - -
Other current liab 5.62M 6.98M 0.65M 9.75M 11.52M
Common stock 201.87M 179.34M 148.52M 147.55M 142.92M
Capital stock 201.87M 179.34M - 147.55M 142.92M
Retained earnings -213.07298M -179.25410M -142.57680M -114.44851M -83.51786M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M - -
Cash 21.42M 30.58M 34.87M 59.47M 83.90M
Cash and equivalents - - - - -
Total current liabilities 5.66M 7.01M 8.30M 9.80M 11.57M
Current deferred revenue - - - - -
Net debt -21.29116M -30.42150M -34.69556M -59.39700M -83.78149M
Short term debt 0.04M 0.03M 0.02M 0.05M 0.04M
Short long term debt - - - - -
Short long term debt total 0.13M 0.16M 0.17M 0.07M 0.12M
Other stockholder equity 29.08M 24.65M 18.79M 19.10M 16.84M
Property plant equipment - - - 0.30M 0.36M
Total current assets 23.50M 31.67M 36.15M 61.44M 87.14M
Long term investments - - - - -
Net tangible assets - - - 51.91M 75.86M
Short term investments - - 0.06M - -
Net receivables 0.23M 0.36M 0.28M 0.48M 0.41M
Long term debt - - - - -
Inventory - - - - 0.34M
Accounts payable - 6.98M 7.62M 9.33M 4.14M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 3.52M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - -0.00000M - -
Deferred long term asset charges - - - - -
Non current assets total 0.12M 0.20M 0.55M 0.59M 0.74M
Capital lease obligations 0.13M 0.16M - 0.07M 0.12M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.02129M -0.10144M -0.07471M -0.01292M
Change to liabilities - - - 4.47M 2.39M
Total cashflows from investing activities -0.02448M -0.02129M -0.06431M -0.07471M -0.01292M
Net borrowings -0.05538M -0.04153M -0.05538M -0.05393M -0.05192M
Total cash from financing activities 15.54M 18.84M -0.05538M -0.05393M 93.44M
Change to operating activities - - - 1.42M -2.27459M
Net income -33.81887M -36.67730M -28.12829M -30.93065M -31.63824M
Change in cash -9.16334M -4.35175M -24.53809M -24.42920M 69.87M
Begin period cash flow 30.58M 34.93M 59.47M 83.90M 14.03M
End period cash flow 21.42M 30.58M 34.93M 59.47M 83.90M
Total cash from operating activities -23.85465M -25.06087M -25.18044M -27.22034M -23.55078M
Issuance of capital stock 16.04M 21.36M 0.00000M 0.00000M 84.08M
Depreciation 0.10M 0.37M 0.25M 0.22M 0.22M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - 0.00000M 0.00000M 0.02M
Change to account receivables 0.14M -0.08175M 0.20M -0.14418M -0.05995M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.47703M -2.47372M 0.06M -0.07471M 9.41M
Change to netincome - - - -2.25762M 7.79M
Capital expenditures 0.02M 0.02M 0.06M 0.07M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.73334M -0.93156M -0.54588M 5.75M 0.08M
Stock based compensation 10.70M 14.28M 4.16M 5.01M 8.50M
Other non cash items -0.10533M -2.10252M -0.91139M -7.27081M -0.70731M
Free cash flow -23.87913M -25.08216M -25.24475M -27.29505M -23.56369M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CRDL
Cardiol Therapeutics Inc Class A		 - -% 1.06 - - 1014.87 13.00 293.71 0.30
ZTS
Zoetis Inc		 -2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 - -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc Class A

2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5

Key Executives

Name Title Year Born
Mr. David G. Elsley M.B.A., MBA Pres, CEO & Director NA
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, M.B.A., MBA CFO, Corp. Sec. & Director NA
Mr. Bernard Lim B.Sc. Chief Operating Officer NA
Dr. Andrew Warwick Hamer M.D. Chief Medical Officer & Head of R&D 1962
Trevor Burns Investor Relations NA
Mr. David G. Elsley MBA President, CEO & Director NA
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA CFO, Corporate Secretary & Director NA
Dr. Andrew Warwick Hamer M.D. Chief Medical Officer & Head of Research & Development 1962
Mr. Christopher J. Waddick C.A., C.M.A., CPA, MBA CFO, Corporate Secretary & Director NA
Dr. Andrew Warwick Hamer M.D. Chief Medical Officer and Head of Research & Development 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.